Nexium, Esomeprazole News

Popular antacids known as proton pump inhibitors , or PPIs , may cause or aggravate the very acid-reflux symptoms they're used to treat, according to a new study.

After proton pump inhibitor therapy is withdrawn, patients may be likely to experience acid-related symptoms, according to a study published in the July issue of Gastroenterology .

Jun 30, 2009 - POZEN Inc. , today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the marketing approval of VIMOVO , the combination of enteric coated naproxen and immediate release esomeprazole.

New Study Shows Nexium 40 Mg And 20 Mg Reduced Gastric And Duodenal Ulcers By 80 - 85% In Patients Taking Low-Dose Aspirin For CV Protection Esomeprazole significantly reduced the occurrence of gastric and duodenal ulcers and upper gastrointestinal symptoms in patients taking low-dose aspirin for risk reduction of adverse cardiovascular events[i], ...

Two studies from AstraZeneca show that symptomatic gastroesophageal reflux disease patients treated with NEXIUM 20 mg daily experienced greater relief from nighttime heartburn and GERD-related sleep disturbances compared with patients taking placebo over four weeks .

Heartburn is ailing the masses. By one estimate, 20 percent of the Western population experiences acid reflux at least once a week.

It's not until you read the Indian press that it dawns on you what a total disaster Ranbaxy is - and by extension its deal to supply AstraZeneca with a Nexium ingredient.

Minakem Group, through its holding company Minafin, has completed the acquisition of a multi-purpose APIs plant, formerly owned by AstraZeneca and has signed with the latter a long-term supply contract for Budesonide, Omeprazole and Esomeprazole.

A new study has added to the concern that commonly used proton-pump inhibitors may interfere with Plavix in people who have coronary artery disease.

WILMINGTON,A Del. Anglo-Swedish drug maker AstraZeneca announced Monday that it had submitted an approval application to the Food and Drug Administration for a low-dose medication designed to reduce the risk of gastric and duodenal ulcers associated with low-dose aspirin.

Four of the most commonly prescribed heartburn medications reduce the benefit associated with clopidogrel, a widely used antiplatelet medication also known by its brand name, Plavix.

The anti-clotting action of the medication clopidogrel can be compromised by common drugs for the treatment of heartburn and ulcers resulting in a roughly 50% increase in the combined risk of hospitalization for heart attack, stroke and other serious cardiovascular illnesses, according to a new study presented today at the Society for ...

Main Category: GastroIntestinal / Gastroenterology Also Included In: Regulatory Affairs / Drug Approvals Article Date: 05 May 2009 - 8:00 PDT AstraZeneca announced today that it has completed the Mutual Recognition Procedure in Europe with Sweden as Reference Member State for the use of Nexium to prevent peptic ulcer re-bleeding in adults.1 Nexium ...

AstraZeneca has announced the submission of a new drug application to the U.S. Food and Drug Administration seeking approval for a product combining low dose aspirin with esomeprazole magnesium for the risk reduction of low dose aspirin-associated gastric and/or duodenal ulcers in patients at risk.

This week's New England Journal of Medicine examines the efficacy of esomeprazole for treatment of poorly controlled asthma.

A commonly used treatment for acid reflux does not improve asthma symptoms or control in patients who do not have symptoms of gastroesophageal reflux , according to a new study supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health and by the American Lung Association .

New research suggests that a widely used treatment for persistent acid reflux among asthmatics doesna t actually improve their quality of life.

According to researchers in the U.S. millions of asthma patients taking the drug Nexium, , or a similar drug are doing so unnecessarily.

April's issue of the Annals of Internal Medicine investigates intravenous esomeprazole for the prevention of recurrent peptic ulcer bleeding.

A new study in this week's New England Journal of Medicine suggests that treating asymptomatic gastroesophageal reflux disease with a proton-pump inhibitor in patients with poorly controlled asthma does not improve asthma control.